H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report  by Gersner, R. et al.
Epilepsy & Behavior Case Reports 5 (2016) 52–56
Contents lists available at ScienceDirect
Epilepsy & Behavior Case Reports
j ourna l homepage: www.e lsev ie r .com/ locate /ebcrCase ReportH-coil repetitive transcranial magnetic stimulation for treatment of
temporal lobe epilepsy: A case reportR. Gersner a,c,1, L. Oberman b,1, M.J. Sanchez a, N. Chiriboga a, H.L. Kaye a, A. Pascual-Leone c, M. Libenson a,
Y. Roth d, A. Zangen d, A. Rotenberg a,c,⁎
a Neuromodulation Program, Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States
b Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, United States
c Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
d Department of Life Sciences, Ben-Gurion University, Beer-Sheva, IsraelAbbreviations: EEG, electroencephalogram; FDA, Fo
MMSE, Mini-mental State Exam; MRI, magnetic res
threshold; rMT, resting MT; TLE, temporal lobe epileps
stimulation; rTMS, repetitive TMS.
⁎ Corresponding author at: 300 Longwood Ave, Fega
Boston Children's Hospital, Boston, MA 02115, United S
fax: +1 617 730 0463.
E-mail address: alexander.rotenberg@childrens.harvar
1 Contributed equally to this study.
http://dx.doi.org/10.1016/j.ebcr.2016.03.001
2213-3232/© 2016 The Authors. Published by Elsevier Ina b s t r a c ta r t i c l e i n f oArticle history:
Received 4 February 2016
Received in revised form 29 February 2016
Accepted 4 March 2016
Available online 16 March 2016Low frequency repetitive TMS (rTMS) of a cortical seizure focus is emerging as an antiepileptic treatment. While
conventional rTMS stimulators activate only superﬁcial cortical areas, reaching deep epileptic foci, for example in
temporal lobe epilepsy (TLE), is possible using specially designed H-coils. We report the results of rTMS in a
young adultwith pharmacoresistant bilateral TLEwho underwent three courses (of 10, 15, and 30 daily sessions)
of unilateral rTMS over the hemisphere from which seizures originated most often. Seizure frequency was
assessed before and after each block of rTMS sessions, as was the tolerability of the procedure. Seizure frequency
declined signiﬁcantly, by 50 to 70% following each rTMS course. All sessions were well-tolerated.
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Transcranialmagnetic stimulation (TMS) is a safe andwell-tolerated
method for noninvasive focal cortical stimulation where small intracra-
nial electrical currents are generated by a rapidly ﬂuctuating extracrani-
al magnetic ﬁeld [1,2]. Repetitive TMS (rTMS) stimulates the brain with
a series of magnetic pulses and has an inhibitory effect on the neuronal
activity when applied at a low (≤1 Hz) frequency [3]. Low frequency
rTMS applied for 15–30 min can reduce regional cortical excitability,
and when targeted to an epileptic focus, this can suppress seizures in
patients with neocortical epilepsy [4,5] and interrupt ongoing seizures
in status epilepticus [6,7]. However, in patients with temporal lobe epi-
lepsy (TLE), rTMS has failed to achieve reliable therapeutic effects [8],
presumably because of its inability to reach a deep-seated seizure focus.
Recently, a special H-coil versionwas developed to target deep areas
of the temporal lobe. Deeper and larger volumes of stimulation can be
induced by the unique shape of H-coils containing an array of elements
which are contoured to the shape of the skull [9]. The H-coil has beenod and Drug Administration;
onance imaging; MT, motor
y; TMS, transcranial magnetic
n 9, Department of Neurology,
tates. Tel.: +1 617 919 2763;
d.edu (A. Rotenberg).
c. This is an open access article undersuccessfully evaluated in terms of safety and efﬁcacy of extratemporal
cortical stimulation, is Food and Drug Administration (FDA)-approved
for treatment of major depression [10–12], and is undergoing active
evaluation in other disease states [13–16]. In the current study, we
employed a system, previously tested in a saline phantom model, but
not applied clinically, which we speciﬁcally adapted for mesotemporal
lobe stimulation as an effort to test the safety and efﬁcacy of 1-Hz
rTMS in TLE.
Here, we describe a patientwith pharmacologically intractable bilat-
eral TLE whose seizures improved after H-coil rTMS. Case details are
below.
2. Case report
A 25-year-old woman, cared for at Boston Children's Hospital, pre-
sented with initial seizure onset at age 14 years. Her most frequent sei-
zure semiology was characterized by behavioral arrest and staring
episodes, occurring initially approximately four times per week, with
each seizure lasting 20–30 s. Each seizurewas accompanied by a subjec-
tive sensation of lost time or confusion. While amnestic for content of
individual seizures, the patient was aware that a seizure had occurred
and maintained a careful seizure diary. Her ability to identify her own
seizures after the fact was conﬁrmed by her family members and peri-
odic video-EEGmonitoringduringwhich these seizureswere conﬁrmed
as epileptic. At the time of her visit, the frequency had since increased to
multiple daily seizures. On EEG, she had bilateral independent seizure
onsets from the left and right temporal regions. Her seizures persisted(http://creativecommons.org/licenses/by-nc-nd/4.0/).the CC BY-NC-ND license
Fig. 1. Schematic of right hemisphere H12 coil in prime position. Note the relatively broad
distribution of the stimulating elements over the right hemisphere.
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mazepine, and oxcarbazepine.
The patient's workup also included a normal physical exam, normal
brain MRI, and EEGwhich showed interictal spikes in the bilateral tem-
poral regions, and seizures originating as left or right temporal sharply
contoured theta slowing progressing to spike and wave in the temporal
region of origin before either termination or secondary generalization.
Her past medical history was otherwise unremarkable with normal de-
velopment from birth and normal IQ.
3. Materials and methods
3.1. Timeline
Written informed consent was obtained before recruitment into the
trial at Boston Children's Hospital (Boston, MA). During the initial pre-
treatment phase (baseline, 28 days prior to initiation of rTMS) and fol-
lowing the treatment process (follow-up, 28 days following rTMS),
the patient was asked to keep a seizure diary in which she was
instructed to record each seizure she experienced. Following each treat-
ment session, safety and tolerability questionnaires were completed by
the participant, and the Mini-mental State Examination (MMSE) was
administered.
The patient underwent three H-coil rTMS treatment courses be-
tween 2013 and 2015. The stimulating coil operates in either sham or
verum mode, and for the ﬁrst course of daily H-coil rTMS, the subject
was blinded to the condition. Stimulation for the ﬁrst course consisted
of ten individual sessions. The patientwas unblinded as to the condition
for the second and third rTMS courses, where active stimulationwas de-
livered for 15 and 30 sessions, respectively.
3.2. Treatment
As seizures arose more often from the right temporal lobe than from
the left, the right side was chosen as the therapeutic focus. During each
30-minute daily session, 1800 pulses were applied at 1 Hz using the
H12-coil (Brainsway Inc., Jerusalem, Israel; Fig. 1) which was speciﬁcal-
ly designed for this study with the focus of stimulation over the right
temporal region (Fig. 1). The coil was embedded in a helmet that
was positioned over the patient's scalp as previously described for the
H-coil system [10,12]. While the precise anatomy of the stimulated re-
gion is not known, an approximation is that, at 120% of the patient's
resting motor threshold (rMT), neural activation is induced mainly
over the right temporal lobe, where the ﬁeld intensity is maximal,
and also in prefrontal and parietal regions. Stimulation of the extra-
temporal regions is required to induce the broad and deep stimulation
with an H-coil.
The patient's rMT, the lowest intensity of stimulation required to
elicit amotor response of theﬁngerﬂexors in 5 out of 10 consecutive tri-
als, was determined by visual inspection of the handduring stimulation.
For rMT measures, the coil was tilted such that the stimulating compo-
nents were displaced rostrally from the temporal region toward the
centroparietal area. Once rMT was obtained, the coil was tilted to the
prime position with the active portion of the electromagnet over the
right temporal region. rTMS was delivered at maximal-tolerated inten-
sities (83%–110% rMT, see Results).
3.3. Patient assessment
At each rTMS session, the patient completed a side effects question-
naire. Speciﬁcally, presence and severity of headache, neck pain, and
scalp pain/irritation were assessed before and after each rTMS session.
In addition, after each rTMS session, the patient reported whether she
had trouble hearing, thinking, or concentrating, or had changes in
mood, or had any other subjective symptoms compared to before the
start of the session.3.4. Data analysis
The subject maintained a seizure diary and recorded seizures dig-
itally using Seizure Tracker online software (www.seizuretracker.
com). All reported seizures were classiﬁed as either isolated seizures
or seizure clusters. For purposes of analysis, a seizure cluster was
deﬁned by a group of seizures with no more than 15 min between
each individual seizure. In these instances, the patient was aware
that greater than one seizure had occurred but was amnestic for
the precise number. Thus, we counted both the standalone seizures
and seizure clusters. Results are presented as means ± SEM.
Mann–Whitney U test was used to analyze changes in seizure
frequency following each rTMS course and to analyze the relapse
during follow-up.4. Results
4.1. Tolerability
Given that the only other FDA-approved H-coil protocol – for pre-
frontal cortex stimulation – suggests stimulating at 120% rMT, we
intended to gradually increase stimulation intensity to 120% of rMT in
our patient. However, the stimulation intensity was less than 120%
rMT. During the patient's ﬁrst rTMS course, while rMT was 59% of ma-
chine output (MO), stimulation at intensity N49%MO (83% rMT) caused
54 R. Gersner et al. / Epilepsy & Behavior Case Reports 5 (2016) 52–56discomfort. Similarly, during the second and third rTMS courses, though
tolerability increased, stimulation intensity was limited by patient dis-
comfort and reached 56% MO (100% rMT) in course 2 and 74% MO
(110% rMT) in course 3. The patient's maximal tolerable stimulation in-
tensity did not reach 120% rMT because of pain and discomfort in the
right jaw and face region.Fig. 2.Daily seizure count before and after rTMS. Number of single seizures and seizure clusters (
and third (C) rTMS courses. Black arrow marks the treatment block with associated number o4.2. Adverse events
The patient otherwise tolerated daily H-coil rTMS sessionswell with
few minor adverse events. More speciﬁcally, she reported headache
(following 4 out of total 55 daily sessions), neck pain (8 of 55), anxiety
(1 of 55), and mild scalp irritation (1 of 55). The anxiety and mild scalpgray and black parts of stacked columns, accordingly) before and afterﬁrst (A), second (B),
f sessions.
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resolved spontaneously andwas of short (minutes) duration. In addition,
throughout all treatment courses, the results of her MMSE were stable
and remained within normal range (28–30). The patient did not report
changes in hearing, thinking, or concentrating ability; however, following
4 out of 55 daily sessions, the patient did report improved mood.
4.3. Efﬁcacy
Single seizures, seizure clusters, and total number of seizures were
recorded at baseline and follow-up in all treatment sessions (Fig. 2). Fol-
lowing each rTMS course, we found a 50–70% reduction of single (p =
0.003, p b 0.001, and p = 0.013 following ﬁrst, second, and third rTMS
course, accordingly) and total (p b 0.001 following all 3 rTMS courses)
number of seizures (Fig. 3A and C, correspondingly). The number ofFig. 3. The effect of H-coil rTMS on seizure count. Data are presented as mean ± SEM of
baseline (black) and follow-up (white) single seizures (A), seizures cluster (B), and total
seizure count (C). Both single seizures (A) and total seizure count were reduced
following all three treatment blocks. Seizure cluster (B) reduction displayed following
ﬁrst and third but not second treatment block. * p b 0.05, **p b 0.01, ***p b 0.001 as
compared to baseline.clusters (Fig. 3B) was reduced signiﬁcantly after the ﬁrst (p b 0.001),
and clusters were absent after the third (p b 0.001) rTMS session (Fig.
3B).
In addition, following theﬁrst (but not second or third) rTMS course,
we found a gradual relapse in the number of clusters (p = 0.017) and
total number of seizures (p= 0.016) suggesting a more sustained anti-
seizure effect of the second and third treatments (Fig. 2).
5. Discussion
We present a patient with pharmacoresistant TLE, in whom signiﬁ-
cant seizure reduction followed repeated H12-coil 1-Hz rTMS. Stimula-
tion was safe and relatively well-tolerated in this patient. Previous
studies using conventional ﬁgure-of-eight coils indicate that low fre-
quency rTMS can suppress seizures originating from a superﬁcial, neo-
cortical focus [4,5]. However, rTMS with a ﬁgure-of-eight coil was
ineffective in a trial aimed to test rTMS antiepileptic potential in TLE
[8]. One possible explanation of differential outcomes may be the loca-
tion of seizure focus, speciﬁcally the seizure focus depth relative to the
skull surface. While affected regions in neocortical epilepsy are up to
2 cm deep from the skull, the affected regions of TLE may be consider-
ably deeper, particularly in cases with a mesial temporal lobe seizure
focus. Thus, our rationale was to test efﬁcacy of the H-coil TMS system,
which can effectively stimulate regions up to 6 cm deep beneath the
skull surface [9,17]. And indeed, our study shows that H-coil stimulation
might be effective in seizure suppression in some patients with TLE.
Another plausible explanation for difﬁculty with suppressing sei-
zures by rTMS in TLE is the size of the epileptogenic network, which in
many cases encompassesmore than just themesial temporal structures
[18,19] and involves appreciable portions of the remaining temporal
lobe and extratemporal structures. Here too, the H-coil, which enables
not just deep but also broad stimulation that likely activates temporal
as well as some extratemporal structures, may be advantageous.
In addition to documenting seizure improvement in TLE after H-coil
rTMS, our study may be the ﬁrst to report serial rTMS in a patient with
epilepsy, in this case with progressive increases in relative intensity and
duration rTMS protocols. Also in contrast to many case reports, the pa-
tient was blinded as to whether she received verum or sham rTMS dur-
ing the ﬁrst treatment block. We note that, although the second and
third treatment courses were open label, their efﬁciency was not signif-
icantly different from the single-blinded ﬁrst treatment block suggest-
ing minimal placebo effect.
As we increased the duration of rTMS courses from 10 to 15 to 30
stimulation days, we observed that seizure reduction was stable: sei-
zure frequency declined by 50–70% after each rTMS course. However,
the second and third prolonged rTMS courses did correspond to longer
time to relapse, suggesting either a cumulative therapeutic effect of re-
current treatment blocks or greater seizure suppression with rTMS
course that contained more stimulation days/sessions. Of course, these
interpretations should be taken with caution as the patient was not
blinded to the treatment condition in courses 2 and 3.
While too early for a deﬁnitive analysis of efﬁcacy, our report indi-
cates the feasibility of using H-coil rTMS to suppress TLE seizures and
underscores a future utility of a large randomized, controlled trial.
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